Skip to main content
. Author manuscript; available in PMC: 2013 Sep 3.
Published in final edited form as: Lancet. 2012 Jun 30;379(9835):2466–2476. doi: 10.1016/S0140-6736(12)60436-X

Table 4.

Internationally available oral killed cholera vaccines

Vaccine Doses* Dosing
interval* 		Dosing
volume* 		Boosters* Protective
efficacy		 Comments References
Dukoral** (Crucell)

  • Pre-qualified for use by WHO

  • Licensed in many countries

  • Has been safely administered to individuals infected with HIV

  • Provides short-term protection against diarrhea caused by heat labile toxin (LT) expressing strains of enterotoxigenic E. coli (ETEC)

 (106– 111;145;146)
Children 2 – <6 years of age 3 14 days (7– 42 permissible) 3 ml Vaccine and 75 ml buffer Every 6 months 60–85% Protective Efficacy within 6 months of vaccination,
>6 years of age 2 14 days (7– 42 permissible) 3 ml Vaccine and 150 ml buffer Every 2 years decreasing to baseline over 24–36 months
Shanchol (Shantha Biotechnics-Sanofi Pasteur) (105;112– 115;147; 148).
60–70% Protective efficacy over 24–36

  • Pre-qualified for use by WHO

  • Currently more affordable than Dukoral

  • Does not require buffer to administer vaccine

  • Currently undergoing field studies in Kolkata/Orissa, India and Dhaka, Bangladesh, and pilot roll out in Haiti
>1 year of age 2 14 days (window probably same as Dukoral) 1.5ml Every 2 years months
*

Per manufacturer

**

Listed field studies have involved both the current preparation of WC-rBS vaccine, supplemented with recombinant cholera toxin B subunit (rBS), and a previously available preparation of WC-BS containing non-recombinant B subunit (BS).